MA
PEARW

MYDA Advisors’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

MYDA Advisors’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,162
Closed -$9K – 229
2022
Q2 		$9K Hold
57,162
– – ﹤0.01% 195
2022
Q1 		$45K Sell
57,162
-2,838
-5% -$1.99K 0.02% 183
2021
Q4 		$36K Buy
+60,000
New +$60.9K 0.01% 235

Other funds holding PEARW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

MYDA Advisors's PEARW Position: Q3 2022 in Review

MYDA Advisors sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q3 2022, closing a stake of 57,162 shares — an estimated $9K sold.

MYDA Advisors first reported a position in PEARW in Q4 2021 and held it in 3 quarters. The position peaked at $45K in Q1 2022. 36 funds tracked by Wall St. Rank hold PEARW as of Q3 2022.

  • MYDA Advisors reported no remaining Pear Therapeutics, Inc. Warrant position as of Q3 2022 after selling out during the quarter.
  • MYDA Advisors sold 57,162 Pear Therapeutics, Inc. Warrant shares in Q3 2022, an estimated $9K.
  • MYDA Advisors first reported a position in Pear Therapeutics, Inc. Warrant in Q4 2021 and held it in 3 quarters.
  • MYDA Advisors's Pear Therapeutics, Inc. Warrant position peaked at $45K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q3 2022.

Based on MYDA Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.